Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland [Yahoo! Finance]
Lantheus Holdings, Inc. (LNTH)
Last lantheus holdings, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.lantheus.com/investor-relations
Company Research
Source: Yahoo! Finance
PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that patients in Poland received the first doses of PYLCLARI ® (INN: Piflufolastat ( F) also known as F-DCFPyL). PYLCLARI ® is a diagnostic medicine used in adults to detect prostate cancer cells in patients with high-risk prostate cancer prior to initial curative therapy, and to localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent. Manufacturing and distribution of the product is managed by Curium's new Partner Synektik Pharma Sp. z o.o. Ciril Faia, CEO Curium International, said: “We are extremely pleased with today's news that PYLCLARI ® is now available to patients with prostate cancer in Poland. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, the growing availability of PYLCLARI ® in Europe
Show less
Read more
Impact Snapshot
Event Time:
LNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LNTH alerts
High impacting Lantheus Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LNTH
News
- Truist Sees Upside in Lantheus Holdings, Inc. (LNTH) Despite PYLARIFY Pressure [Yahoo! Finance]Yahoo! Finance
- Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $82.00. They now have a "buy" rating on the stock.MarketBeat
- Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Mizuho from $60.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
- Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas [Yahoo! Finance]Yahoo! Finance
- Reassessing Lantheus Holdings After Recent Share Price Volatility and Cash Flow Outlook [Yahoo! Finance]Yahoo! Finance
LNTH
Earnings
- 11/6/25 - Beat
LNTH
Sec Filings
- 12/17/25 - Form 4
- 12/12/25 - Form 144
- 11/26/25 - Form 144
- LNTH's page on the SEC website